Ultragenyx Pharmaceutical
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$23.31
FAIR PRICE
$53.21
MARGIN
$29.90
P/E Ratio
N/A
Div. Yield
N/A
ROE
-411.0%
Average
Market Cap
$2B
Mid-cap
NOW AVAILABLE
Get notified when RARE's fair price changes
Push notifications when RARE's valuation shifts. Available on iOS and Android.
FPI RATING
Challenges include weak profitability margins and volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$42.57
Fair price × 0.80
DISTANCE
82.6%
Price to entry level
At the current price of $23.31, RARE trades 82.6% below the conservative entry level of $42.57. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate RARE's fair price
Ultragenyx Pharmaceutical's fair price of $53.21 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $23.31, RARE trades 128.3% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting RARE's risk profile.
RELATIVE · 30%
Comparing RARE's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for RARE, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate RARE's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for RARE.
Explore on BuliosFAQ
What is the fair price of RARE?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Ultragenyx Pharmaceutical is $53.21. At the current market price of $23.31, RARE trades 128.3% below its calculated fair value.
Is RARE overvalued or undervalued?+
Ultragenyx Pharmaceutical is currently undervalued based on our valuation model. The stock trades at $23.31, which is 128.3% below the fair price of $53.21.
What is the margin of safety for RARE?+
With a 20% margin of safety applied to the fair price of $53.21, the conservative entry level for RARE is $42.57. At the current market price of $23.31, the stock trades 82.6% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is RARE's fair price updated?+
We update fair price calculations for RARE daily after market close. The current fair price of $53.21 incorporates the latest market data and sector multiples.
What factors affect RARE's fair price calculation?+
RARE's fair price of $53.21 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -411.0%.
Is RARE a good buy right now?+
At $23.31, RARE trades 128.3% below our fair value estimate of $53.21. The stock is currently undervalued. ROE stands at -411.0% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does RARE pay dividends?+
RARE does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.